|
|
|
|
|
| Papers |
September 15, 2006
|
|
|
|
|
|
| Email |
SabahK@marcusevanscy.com
|
|
| Category |
Science: Life_Sciences
|
|
| Category 2 |
Science: Biotechnology
|
|
|
|
|
|
|
|
|
|
|
| Description |
The 5th Annual Evolution 2006 Summit is an annual event, part of our life science series, complementing our annual Discovery 2006 Summit. The 5th Annual Evolution 2006 Summit offers senior clinical trials executives an exclusive opportunity to interact with their peers through a balanced programme of keynote addresses, presentations, discussion sessions and workshops. The event also includes one-to-one pre-scheduled business meetings with key solution providers and informal networking. To maximise the value to each attendee, delegates will be able to view full details of the programme prior to the event in order to specify their preferred sessions and meetings, and therefore devise their own personal schedule.
A Unique Event Format
The race to get new drugs to market faster and more cost effectively is the principal driver of the European pharmaceutical industry. In the past years the industry has been driven to challenge its traditional strategies as crucial issues emerge.
One of the main transformations is the introduction of the EU Directive in May 2004. Recent drug withdrawal from the market has challenged the industry as well as the regulators in being more transparent with clinical trials findings. Therefore GCP and Quality Assurance are even more pressing concerns to address in order to stay ahead in the market. Furthermore the globalisation of the industry has seen a greater growth of outsourcing of patient recruitment and clinical trials. A number of emerging technologies such as micro-dosing are enabling the industry to work towards its aim of less time and cost to market.
In its fifth year running, the Annual Evolution Summit is the key European event attracting all the players to explore the best practises in European clinical trials processes.
The Summit Programme: The wide variety of summit sessions will enable delegates to explore new strategies and technologies critical to the development of the clinical trials process. The programme is put together through extensive on-going research with delegates, industry experts and relevant parties to ensure that its content is relevant and accurately reflects their needs and interests.
|
|
|
|
